Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
Cavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, Moores SL, Marquez-Nostra B. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 383-394. PMID: 32770372, PMCID: PMC7855369, DOI: 10.1007/s00259-020-04978-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEpidermal growth factor receptorPET/CTMDA-MB-468MDA-MB-231C-MetGrowth factor receptorIsotype controlBreast cancerMDA-MB-468 xenograftsBispecific antibodiesC-Met expression levelsHCC827 lung cancer cellsMono-targeted therapiesFactor receptorLevels of EGFROptimal imaging time pointC-Met expressionNovel bispecific antibodyStandard uptake valueRadioligand binding studiesExpression levelsLung cancer cellsMDA-MB-453Imaging time point[89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.Peer-Reviewed Original ResearchMeSH KeywordsGlycoproteinsHumansMelanomaMembrane GlycoproteinsPositron-Emission TomographyRadioisotopesTriple Negative Breast NeoplasmsZirconiumConceptsStandardized uptake valueTriple-negative breast cancerWeeks of treatmentCDX-011Tumor modelBreast cancerMelanoma BPretreatment standardized uptake valueAntibody-drug conjugate (ADC) therapyPatient-derived tumor modelsNegative breast cancerSingle bolus injectionPositron emission tomographyTumor regrewPretreatment PETADC therapyPrognostic markerBolus injectionTumor volumeSUV ratioRadiotracer uptakeUptake valueStrong inverse correlationTumor typesPercent change